A blockbuster cancer drug? TYK’s claims go under the microscope
The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme Key Takeaways: The drug being developed…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
AstraZeneca could face limited fallout from Chinese tax probe
AZN.US
- IPO pitch puts BrainAurora’s earnings under the microscope
-
NEWS WRAP: AstraZeneca China president assisting in investigation
AZN.US
